ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

Subramaniam vs Subramanian

Has Profit Taken Precedence Over People?

The private assurances supposedly given by the Indian government to the United States-India Business Council that it would not grant compulsory licences to Indian drug makers for commercial purposes except in cases of public health emergencies negate the intent of the Indian intellectual policy regime to work patents in India and provide affordable medicines to people.

On 22 June 2016, Subramaniam Swamy tweeted: “Who said to US Cong on 13/3/2013 the US should act against India to defend US Pharmaceuticals interests? Arvind Subramanian MOF!! Sack him!!”

Expectedly, an animated discussion followed. In keeping with the traditions of the Lutyens zone in Delhi, it revolved around the personalities involved. Not unexpectedly, in an era of instant news, the din soon subsided.

Dear Reader,

To continue reading, become a subscriber.

Explore our attractive subscription offers.

Click here


To gain instant access to this article (download).

Pay INR 50.00

(Readers in India)

Pay $ 6.00

(Readers outside India)

Back to Top